Aurora Cannabis Inc Stock Price, News & Analysis

Aurora Cannabis (NASDAQ: ACB) held its 2025 Annual General and Special Meeting with 31.53% shareholder participation, representing 17.7 million shares. Five of six director nominees were successfully elected to the board, while Theresa Firestone resigned following a failed re-election bid with only 42.4% votes in favor.

The company announced key leadership changes, with Michael Singer appointed as new Lead Independent Director and Chair of the Human Resources and Compensation Committee. Shareholders approved Ernst & Young LLP as auditors and amendments to the company's RSU, PSU, and Share Option Plans. Notably, the "say-on-pay" advisory vote on executive compensation failed to receive majority support.

Aurora Cannabis (NASDAQ: ACB), Canada's largest medical cannabis company, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. CFO Simona King will engage in a fireside chat on August 13th at 1:30pm EST and hold one-on-one investor meetings.

The presentation will focus on Aurora's strategic direction, recent achievements, and growth prospects in the global medical cannabis market. Investors can access the live webcast through Aurora's investor relations website, with replay available for 90 days.

Aurora Cannabis (NASDAQ:ACB) reported strong Q1 2026 results, with total net revenue reaching $98.0 million, up 17% year-over-year. The company's global medical cannabis segment showed impressive growth, with revenue increasing 37% to $64.8 million, driven by an 85% surge in international markets.

Key financial highlights include Adjusted EBITDA of $10.8 million (up 209% YoY), positive free cash flow of $9.2 million (up 42%), and adjusted gross margin of 52%. The company maintains a strong balance sheet with $186.0 million in cash and a debt-free cannabis business.

International medical cannabis now represents 57% of global medical cannabis revenue, with significant growth in Germany and Poland. The company's plant propagation business, Bevo, contributed $23.9 million in revenue, showing 4% growth YoY.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has announced its upcoming annual general and special meeting scheduled for August 8, 2025, at 1:00 p.m. Eastern Time. The meeting will be held virtually via live webcast.

The company reminds shareholders to cast their votes before the proxy voting deadline of August 6, 2025, at 1:00 p.m. Eastern Time. The Board of Directors recommends voting in favor of all director nominees and proposed resolutions. Shareholders can access meeting materials on Aurora's website and SEDAR+, with voting available online or by telephone through Laurel Hill Advisory Group.

Aurora Cannabis (NASDAQ: ACB), a leading global medical cannabis company, has announced its upcoming first quarter 2026 earnings conference call. The event will take place on Wednesday, August 6, 2025, at 8:00 a.m. Eastern Time.

The company will release its Q1 2026 financial results before markets open on the same day. The conference call will be hosted by Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, and will include a question and answer session. Investors can access the webcast through Aurora's investor relations website.

Aurora Cannabis (NASDAQ: ACB) has reaffirmed its commitment to veterans through its Strains for Heroes initiative. The company donates 5% of net profits from Strains for Heroes products to veteran organizations annually, capped at C$200,000.

The program, launched in 2022, has developed five purpose-grown cannabis strains named by veterans: Valour, Courage, Honour, Esprit De Corps, and United Victory. Aurora collaborates with veteran communities to create custom strains based on their specific preferences and needs.

The company partners with various veteran organizations including Highway for Heroes, Post Traumatic Growth Association, and True Patriot Love, providing community outreach and charitable support.

Aurora Cannabis (NASDAQ: ACB) has achieved a significant regulatory milestone with its Brampton, Ontario distribution centre receiving EU-GMP certification. This marks Aurora's fourth EU-GMP certified facility within its global network, enhancing the company's international medical cannabis export capabilities.

The certification validates Aurora's compliance with the EudraLex rules for medicinal products in the European Union, demonstrating the company's commitment to maintaining high manufacturing standards and quality consistency. The Brampton facility will serve as a centralized hub for international distribution, optimizing the storage and distribution of medical cannabis products globally.

Aurora Cannabis (NASDAQ: ACB) has announced the filing and distribution of its management information circular for the upcoming annual general and special meeting of shareholders. The virtual meeting is scheduled for August 8, 2025, at 1:00 p.m. ET and will be conducted via live webcast.

The circular is now available on Aurora's website and SEDAR+, with materials being mailed to shareholders of record as of June 16, 2025. Shareholders are urged to vote by the deadline of August 6, 2025, at 1:00 p.m. ET. The board recommends voting FOR all director nominees and meeting resolutions.

Shareholders requiring assistance with voting can contact Laurel Hill Advisory Group, Aurora's proxy solicitation agent, through their toll-free number or email.

Aurora Cannabis (NASDAQ: ACB) has expanded its medical cannabis compassionate pricing program in Canada by increasing the yearly income eligibility threshold from $40,000 to $60,000 CAD. This expansion makes Aurora's program the most inclusive medical cannabis pricing plan in Canada, potentially benefiting over half of the country's adult population.

The company has also introduced new medical cannabis products including Aurora | Mediora Minis (Cannatonic CBD Flower), Daily Special | Sativa J's (THC Pre-Rolls), and WMMC | Seasonal Stash Petro Biscuit (THC Flower). Aurora continues to provide resources for seniors, pediatric patients, veterans, and first responders through their medical cannabis program.